Streetbeat News

Revenues

DELL

Dell Technologies (NYSE:DELL) has significantly outperformed the market over the past 5 years, delivering an average annual return of 29.45%. A $100 investment in DELL 5 years ago would now be worth $363.62. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 5:00 pm

MTUS

Metallus shares are trading lower after the company reported worse-than-expected Q2 financial results and announced expectations for lower Q3 shipments and a less favorable product mix.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 4:59 pm

ASML

ASML Holding (NASDAQ:ASML) has significantly outperformed the market over the past decade, delivering an average annual return of 25.05%. A $1000 investment in ASML 10 years ago would now be worth $9,327.53. The article highlights the power of compounded returns in long-term investments.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 4:30 pm

ASND

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past decade, delivering an average annual return of 49.72%. A $100 investment in ASND 10 years ago would be worth $5,869.77 today. The company's current market capitalization is $7.20 billion.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 4:30 pm

CVS

CVS Health Corp (NYSE:CVS) shares are trading 1.52% lower at $56.97 after reporting worse-than-expected Q2 sales and cutting FY24 adjusted EPS guidance. Sales were $91.23 billion, slightly below the $91.51 billion consensus. Adjusted EPS was $1.83, down from $2.21 last year but above the $1.73 consensus. Operating income fell 16.4% to $3.74 billion. The Health Care Benefits segment’s revenues grew by 21.4%, while the Health Services segment’s revenues dropped by 8.8%. CEO Karen Lynch will take direct control of the Health Care Benefits segment. CVS revised its 2024 adjusted EPS guidance to $6.40-$6.65, down from at least $7.00.

Portfolio Pulse from Henry Khederian

August 09, 2024 | 4:20 pm

NTRA

Natera shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 revenue guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 4:11 pm

AAPL

AMZN

GLD

GOOG

META

MSFT

NVDA

QQQ

SLV

SPY

TSLA

USO

The stock market is experiencing a consolidation phase with mixed money flows in major tech stocks and ETFs. Despite a weak Treasury auction, the market saw a strong oversold bounce driven by short covering. Fed officials are not in favor of an emergency rate cut, and Bitcoin has surged above $60,000. Investors are advised to maintain a protection band and consider tactical positions in bonds.

Portfolio Pulse from The Arora Report

August 09, 2024 | 4:01 pm

NFLX

Netflix (NASDAQ:NFLX) has significantly outperformed the market over the past 20 years, with an annualized return of 32.63%. A $100 investment in NFLX 20 years ago would be worth $28,707.28 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 4:01 pm

CRH

CRH (NYSE:CRH) has outperformed the market over the past 5 years with an average annual return of 20.54%, resulting in a $100 investment growing to $265.64. The company's current market capitalization is $56.77 billion.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 4:00 pm

CRNX

Over the past three months, 11 analysts have shared their evaluations of Crinetics Pharmaceuticals (NASDAQ:CRNX), with a mix of bullish and somewhat bullish ratings. Analysts have set a 12-month average price target of $68.64, reflecting a 7.86% increase from the previous average. Key analysts have adjusted their ratings and price targets, indicating varied perspectives on the company's future performance. Despite challenges in revenue growth and profitability, the company maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 4:00 pm